Rheumatoid Arthritis (RA) – Stem Cells – Regenerative Medicine at Rejuve Anti Aging

Stem Cell and Exosome Therapy for Rheumatoid Arthritis (RA)

Stem Cell Therapy Offers Healing From Within

At Rejuve Anti-Aging, we frequently hear from patients around the world asking whether regenerative therapies can make a difference for those living with Rheumatoid Arthritis (RA). The answer? Absolutely.

Traditional treatments for RA—like steroids, biologics, or immunosuppressants—can help manage pain, swelling, and flare-ups, but they do little to repair the joint damage already caused by chronic inflammation. These approaches often focus on controlling symptoms rather than restoring joint health or promoting long-term healing.

Regenerative medicine is changing that story. Stem cell therapy offers a groundbreaking approach for RA, addressing the overactive immune response, reducing inflammation, and supporting the repair and regeneration of damaged joint tissue. This therapy has the potential to relieve pain, improve mobility, and help some patients achieve lasting improvements in joint function and quality of life. There is hope, and we’re here to guide you toward it.

Struggling with RA symptoms? Call (949) 787-9800 For Help Today!

A Regenerative Approach That Works

Rheumatoid arthritis (RA) is a chronic autoimmune condition that can be life-changing, causing persistent joint pain, swelling, stiffness, and long-term damage. Many patients continue to struggle with daily discomfort and limited mobility even after trying conventional medications. That’s why there’s growing excitement around stem cell therapy—a cutting-edge approach that goes beyond symptom management to address the underlying causes of RA.

Stem cell therapy utilizes mesenchymal stem cells (MSCs) to regulate the overactive immune system, reduce chronic inflammation, and support the repair and regeneration of damaged joint tissue. Unlike medications that can have harsh side effects, stem cells work naturally with your body to restore balance and promote long-term joint health. Clinical studies have shown meaningful improvements in pain, joint function, and overall quality of life for patients with moderate-to-severe RA. At Rejuve Anti Aging, we provide access to the latest in regenerative medicine—offering a therapy that doesn’t just mask your symptoms but works to rebuild and restore your joints from the inside out.

How Stem Cell Therapy May Help With Lupus

Immune System Modulation

Mesenchymal Stem Cells (MSCs), can “reset” the overactive immune response that drives RA. By regulating T cells, B cells, and other immune pathways, they help reduce the autoimmune attack on joint tissues.

Reduction of Inflammation

MSCs naturally secrete anti-inflammatory molecules that lower levels of cytokines like TNF-α, IL-1β, and IL-6. This reduces joint swelling, pain, and tissue damage during flares.

Tissue Repair & Regeneration

MSCs release growth factors that promote repair of damaged cartilage, tendons, and synovial tissue, helping restore joint function and slow disease progression.

Pain Relief & Functional Improvement

By reducing inflammation and supporting tissue healing, MSC therapy can alleviate pain, improve mobility, and enhance overall quality of life for RA patients.

What Is Stem Cell Therapy

Stem cell therapy is an innovative medical treatment that harnesses the regenerative potential of stem cells to repair, replace, or regenerate damaged tissues and organs. Stem cells are unique because they can differentiate into various cell types and multiply indefinitely, making them essential in regenerative medicine and tissue engineering.

Promotes Natural Healing:

By stimulating tissue repair and regeneration, stem cell therapy addresses the root cause of many conditions, supporting the body’s natural healing processes.

Minimally Invasive Procedure:

Typically administered through injections or infusions, stem cell therapy involves minimally invasive techniques, reducing risks and ensuring a faster recovery.

Personalized Treatment Plans:

Each therapy can be tailored to meet individual patient needs, considering their medical history and treatment goals for more targeted outcomes.

Potential for Long-Lasting Results:

While outcomes vary, many patients experience significant and lasting improvements in symptoms, function, and overall quality of life.

See What Studies Have Shown

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that primarily targets the joints but can also affect other tissues and organs throughout the body. Because RA involves both an overactive immune system and ongoing joint and tissue damage caused by inflammation, the most effective treatment would need to address both aspects simultaneously: calming immune activity while also repairing and regenerating damaged tissues. Achieving this dual effect is essential for providing meaningful, long-term relief and improved mobility.

Stem cell therapy offers a unique solution for RA patients. It not only helps to rebalance the immune system and reduce inflammation but also promotes healing and regeneration of damaged joint tissue. This comprehensive approach targets the underlying causes of RA rather than merely alleviating symptoms.

Clinical studies and patient experiences have already shown promising results, with many individuals reporting significant reductions in pain, improved joint function, and enhanced quality of life following stem cell therapy for rheumatoid arthritis.

Study / Approach	Patients	Response / Remission Rates	Follow-up	Key Findings	Notes
Autologous HB-adMSCs (adipose-derived) – Biomed Central, 2022	n=20	Significant improvement in joint function; modest reduction in CRP levels	12 months	Single infusion demonstrated safety and efficacy in active RA patients	Clinical trial NCT03691909; supports adMSC therapy in RA treatment
Allogeneic AT-MSCs – PMC, 2021	n=50	20–45% of patients showed 2% clinical improvement	24 weeks	IV infusion of allogeneic AT-MSCs resulted in modest clinical improvements	Study suggests potential for MSC therapy in RA management
Systematic Review & Meta-Analysis – PLOS ONE, 2023	Multiple trials analyzed	Trend toward clinical efficacy; favorable safety profile without life-threatening events	Varied	Data supports MSC therapy as a potential treatment for RA	Highlights need for high-quality RCTs with extended follow-up
Umbilical Cord Blood MSCs – Stem Cells Translational Medicine, 2014	n=30	Reduction in 28-joint disease activity score	Varied	Single infusion demonstrated efficacy in RA patients	Supports use of umbilical cord-derived MSCs in RA therapy

Stem Cell Technology

Harness the power of cutting-edge regenerative science. Stem cells have the unique ability to transform into any type of cell your body needs, promoting natural healing and cellular repair at the site of application. As the foundation of regenerative medicine, these powerful cells adapt to your body’s needs, accelerating recovery and restoring function.

Ethical Sourcing and Screening

Our stem cell samples are sourced ethically and responsibly from healthy, full-term deliveries. All donor mothers undergo comprehensive social and serology testing to ensure there is no risk of communicable disease. No harm is caused to the mother or child during the collection process, ensuring the highest standards of safety and care.

Specimen Collection

Stem cells are collected exclusively from Wharton’s Jelly, a rich source of regenerative cells found in the umbilical cord. The tissue is obtained during scheduled, healthy C-section deliveries—using a resource that would otherwise be discarded. Each sample is packed with potent stem cells, growth factors, and essential nutrients to support your body’s natural regenerative processes.

Advanced Processing Standards

To maintain maximum potency, Wharton’s Jelly samples are carefully preserved in sterile, cold storage until your treatment. Our entire stem cell collection and processing protocol adheres strictly to FDA and American Association of Tissue Banks (AATB) regulations, ensuring superior quality, safety, and peace of mind.

Why Choose Us?

Patients trust Rejuve Anti Aging for results:

Best-in-Class Stem Cells & Exosomes We use the highest-quality, ethically sourced stem cells and exosomes on the market. Our Stem Cell products ensure maximum potency, purity, and safety for faster, more effective healing.

Cost-Effective Without Compromise: Our prices are competitive with overseas providers. We offer competitive pricing right here in the U.S., so you can receive the highest quality care, close to home, without sacrificing safety or results.

Proven Results: Our patients share stories of reduced pain, improved mobility, and a return to activities they thought they’d lost forever. We’re here to help you get back to living your life—safely, naturally, and with hope.

Call us today to book your free consultation.

Take The First Step & Schedule A Free Consultation

References

1.Phase Ia Clinical Trial (2018) Study Design: Single-center, open-label trial administering intravenous infusion of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) to patients with established RA.

Findings: No short-term safety concerns were observed. Additionally, a reduction in pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α was noted within 24 hours post-infusion.

Reference: Park EH, Lim HS, Lee S, et al. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial. Stem Cells Transl Med. 2018;7(9):636–642. LinkASIPP

2. Three-Year Cohort Study (2019)

Study Design: A cohort study evaluating the long-term efficacy and safety of UC-MSC therapy combined with disease-modifying antirheumatic drugs (DMARDs) in RA patients.

Findings: The combination therapy led to sustained improvements in clinical outcomes, including reduced Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ) scores, and levels of rheumatoid factor (RF), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and anti-cyclic citrullinated peptide (anti-CCP) antibodies over a three-year period.

Reference: Wang Y, Zhang Y, Xu Y, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis: a three-year cohort study. Drug Des Devel Ther. 2019;13:1575–1584. LinkDove Medical PressPubMed

3.Ongoing Phase 1 Study (2025)

Study Design: A multicenter, randomized, double-blind, placebo-controlled Phase 1 trial investigating the safety and efficacy of cultured allogeneic adult UC-MSCs administered intravenously to RA patients

Study ID: NCT05003934

Reference: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA. Link

4. Mechanisms of Action in RA

Immunomodulation: UC-MSCs can modulate the immune system by influencing T lymphocyte activity, thereby reducing inflammation associated with RA.

Reference: Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in collagen-induced arthritis rats and rheumatoid arthritis patients. LinkScienceDirect+1

Cytokine Reduction: UC-MSCs have been shown to reduce levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8, contributing to decreased inflammation and joint damage.

Reference: Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial. LinkASIPP